Rick Simpson Oil (RSO) in Whitfield County, Georgia: The Complete Guide by OilWell Cannabis

If you’re reading this from Dalton, Tunnel Hill, or anywhere across Whitfield County’s rolling foothills, you’re probably looking for honest answers about Rick Simpson Oil. Maybe you heard about it through a friend at church who’s fighting cancer. Maybe your neighbor in Rocky Face mentioned it for their arthritis. Or perhaps you’re one of the many veterans in our community struggling with PTSD after serving our country. Wherever you are in Whitfield County — from the carpet mills of Dalton to the quiet streets of Varnell — we want you to have the full truth about RSO, not the hype you’ve seen online.

We’re OilWell Cannabis, a Houston-based company that ships our lab-tested, multi-cannabinoid RSO formulas directly to Whitfield County and across Georgia. We didn’t start in a corporate boardroom. We started when our founder’s dog Bentley was paralyzed and facing euthanasia, and a rescue worker asked a simple question that changed everything: “You’ve moved how many tons of weed and you’ve never heard of CBD?” That question led to a decade of formulation work, a mission to keep Bentley alive, and eventually the most transparent RSO formulas available today.

This guide is for Whitfield County residents who deserve real education, not snake oil. We’ll walk you through what traditional RSO actually was, why OilWell’s formulas are deliberately different, how our seven-cannabinoid approach works, and most importantly — how you can access it legally here in Northwest Georgia without a medical card.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical professional — he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. For Whitfield County residents who’ve felt let down by conventional medicine after a workplace injury or chronic condition, his story might sound familiar.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. He reported that the medications prescribed either failed to help or made his condition worse. When he asked his physician about cannabis, the request was refused . Many folks in Whitfield County’s manufacturing community know this pattern — workplace injuries, chronic symptoms, and doctors who dismiss cannabis as an option despite the state’s restrictive medical program.

Simpson’s interest in concentrated cannabis oil deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia, where THC reportedly slowed or shrank tumors in mice. That study — originally intended to demonstrate harm — became a foundational reference for Simpson, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment came in 2003. Three bumps on his arm were diagnosed as basal cell carcinoma. Rather than conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and claimed they disappeared within four days. No independent medical verification, biopsy confirmation, or clinical follow-up has ever been published in any peer-reviewed source . Important context: Simpson’s account is personal testimony, not medical evidence, but it became historically significant as the catalyst for a global movement.

The crusade — spreading the oil

After 2003, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free — no charge, no profit. By his account, he helped dozens of people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more . In Whitfield County, where community support networks run deep through church groups and neighborhood connections, this free-distribution model resonates. People help each other here, especially when the medical system falls short.

His story reached a global audience through the 2005 documentary Run From The Cure, which became foundational in cannabis communities. Distributed freely online, it introduced the concept of concentrated cannabis oil as medicine to millions . For many in Dalton’s Latino community who maintain connections to traditional plant medicine, this documentary may have been their first introduction to RSO.

But Simpson’s advocacy brought direct conflict with Canadian law. The RCMP raided his property in 2005 and 2009, charging him with cultivation, possession, and trafficking. Facing continued legal pressure, he eventually left Canada for Europe . This legal risk historically associated with cannabis production is why Georgia’s current hemp regulations and the 2018 Farm Bill matter so much for Whitfield County residents today.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his advocacy platform .

Throughout his career, Simpson maintained that cannabis oil could cure cancer and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge . Important context: His conspiratorial framing is noted here without endorsement — it reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core recommendation was consuming 60 grams of concentrated cannabis oil over approximately 90 days. He considered this the minimum for serious cancer treatment, though he recommended it for numerous conditions .

Goal

Consume 60 grams of high-THC cannabis oil over roughly 90 days.

Titration schedule

• Week 1: Half a grain of rice-sized dose (10-15mg) three times daily — roughly 30-45mg total per day
• Weeks 2-5: Double the dose every four days until reaching 1 gram (1,000mg) per day divided into three doses
• Weeks 5-12: Maintain 1 gram per day until all 60 grams are consumed
• Post-protocol: Maintenance of 1-2 grams per month indefinitely

Administration methods

• Oral: Primary method — sublingual or swallowing for systemic absorption
• Topical: For skin cancers/external lesions, applied directly with bandages
• Not primary: Inhalation for immediate symptom relief only

Important context for evaluating this protocol

• No controlled trial validation — no published randomized controlled trials or well-documented case series
• Crude, unstandardized material — every batch different based on starting plant material
• Very high THC exposure — 600-900mg delta-9 THC daily at peak dosing, far exceeding FDA-approved dronabinol (2.5-20mg/day)
• Real risks — severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, cannabis use disorder
• Oncology complexity — cancer patients are medically complex; using unregulated oil as primary treatment introduces serious harm potential

What is traditional Rick Simpson Oil — the product

Traditional RSO was defined by Simpson’s method, not lab specifications:

Source material

High-THC, indica-dominant cannabis strains with no standardization — availability and growing conditions determined the profile.

Extraction solvent

Naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol — neither food-grade. This is a major safety concern: naphtha may contain benzene, toluene, and other toxic compounds. Incomplete solvent purging leaves harmful residues.

Extraction process

1. Plant material in bucket
2. Cover with solvent and agitate
3. Filter through cheesecloth
4. Repeat with fresh solvent
5. Evaporate solvent in rice cooker at 60-80°C
6. Thick, dark oil remains
7. Transfer to syringes

Appearance

Nearly black, thick, tar-like, sticky oil with strong cannabis odor and possible solvent-residual smell.

Cannabinoid profile

• Fully decarboxylated delta-9 THC dominant (60-90% estimated)
• Minor cannabinoids present at natural ratios but uncontrolled, unmeasured, never lab-verified

Terpene content

Minimal to none — destroyed by solvent extraction and high-heat evaporation.

Standardization and testing

None. Every batch was different with no Certificate of Analysis, cannabinoid quantification, or contaminant screening.

Simpson’s claims vs. the evidence record

Simpson claimed RSO could cure cancer and many diseases. Let’s examine what the evidence actually shows.

What Simpson was not

He was not a scientist, physician, pharmacologist, or researcher. He had no formal medical training, never conducted or published a clinical trial, and never submitted results for peer review. His evidence base was personal experience and informal testimonials with no controls, verification, imaging confirmation, or long-term follow-up.

What the preclinical literature shows

In vitro studies demonstrate THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines. Animal models show some tumor-growth inhibition . These findings are scientifically interesting and generate legitimate research interest.

What the preclinical literature does NOT show

• Findings have NOT translated into proven human cancer cures
• No human clinical trial has demonstrated RSO or any cannabis oil cures cancer
• The gap between lab/animal results and human outcomes is vast

Institutional positions

• NCI: Acknowledges cannabinoid anticancer research in labs/animals but does NOT endorse cannabis as cancer treatment
• FDA: Has NOT approved any cannabis plant product for cancer treatment. Only Epidiolex (CBD) for seizures and synthetic THC analogues for chemo nausea/AIDS wasting are approved [1]
• Health Canada: Has never approved RSO for cancer
• NCCIH: Strongest evidence is for rare epilepsies, chemo nausea, and HIV/AIDS appetite — not cancer cure [1]

What Simpson got right

He drew attention to cannabinoids as serious biomedical research when the world ignored it. His advocacy helped create conditions for today’s legal cannabis industry and research infrastructure. The term “RSO” remains the most recognized name for full-spectrum cannabis extract.

What he overstated

His cure claims exceeded the evidence. Encouraging cancer patients to use RSO instead of proven therapies (surgery, radiation, chemo, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern.

The legacy of Rick Simpson and the evolution of modern RSO

The term “RSO” has become generic. Many products labeled RSO bear little resemblance to Simpson’s original. In dispensaries today, RSO can refer to almost any full-spectrum extract in a syringe.

Simpson criticized commercial products using the RSO name while departing from his method. His model was anti-commercial — give oil away free, teach people to make it themselves . The modern industry has commercialized, standardized, and regulated what Simpson distributed freely. Whether that’s improvement (quality control, testing, precision) or betrayal (profit extraction, gatekeeping) depends on perspective.

What is not in dispute: modern RSO has evolved substantially, and those changes matter for Whitfield County residents evaluating their options.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction solvent	Naphtha or isopropyl alcohol	Food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled (60-90%)	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by heat	Live terpenes at 5% with seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not performed	Full panel: potency, terpenes, pesticides, heavy metals, solvents, microbial
Residual solvents	Significant risk	Controlled and tested
Dosing precision	Approximate syringe-based	Measured per mL (553mg/mL) with graduated dropper
Product formats	Single thick oil	Sublingual oil AND vape cartridge
THCa preservation	No — fully decarboxylated	Yes — 1,500mg THCa as separate ingredient
Evidence approach	Anecdotal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

Multi-cannabinoid approach. Traditional RSO used whatever single strain was available. OilWell’s formulas include seven cannabinoids (CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC) because entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

Terpene preservation. Traditional RSO had essentially no terpenes. OilWell includes live terpenes at 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene) because terpene bioactivity is plausible and supported preclinically, even if human clinical confirmation is still developing [20]-[29].

THCa as separate ingredient. Traditional RSO fully decarboxylated everything. OilWell’s sublingual formula includes 1,500mg THCa, preserving the acidic precursor because THCa literature suggests potentially relevant non-psychoactive bioactivity (COX-2 inhibition, neuroprotection) that is lost when THCa converts to THC [12].

Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. OilWell uses only 90mg delta-9 THC total while distributing cannabinoid content across CBD (4,500mg), CBG (3,000mg), delta-8 THC (6,000mg), THCa (1,500mg), CBN (750mg), and CBC (750mg).

Product format innovation. Simpson envisioned only oral oil from a syringe. OilWell offers both 30mL sublingual oil and 1-gram vape cartridge, acknowledging different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO used naphtha or isopropyl alcohol — not food-grade. Naphtha may contain benzene, toluene, and other toxic compounds. Incomplete solvent purging leaves harmful residues.

Modern extraction uses food-grade ethanol or supercritical CO₂ with validated analytical testing. This addresses the #1 safety concern with traditional RSO. OilWell’s product is not an extract — it’s a formulated blend of individual cannabinoid distillates and isolates in organic MCT oil, with no extraction solvents present. Third-party testing covers potency, terpenes, pesticides, heavy metals, residual solvents, and microbial contaminants.

The decarboxylation question

Traditional RSO was fully decarboxylated by rice cooker heat, converting all THCa to THC. OilWell’s formula preserves THCa as a distinct ingredient.

Three usage options:

• Raw, no heat: All 1,500mg stays as THCa — non-psychoactive for daytime use
• Fully activated: Heat at 260°F for 45-60 minutes converts THCa to ~1,315mg delta-9 THC + existing 90mg = ~1,405mg total delta-9 THC (psychoactive)
• Vape: Auto-decarboxylation at 400-450°F delivers instant activated cannabinoids

The conversion ratio: 1mg THCa = 0.877mg delta-9 THC after decarboxylation.

Terpene loss in traditional RSO

Terpenes volatilize at 21-157°C. Traditional RSO’s solvent evaporation destroyed them. OilWell’s formulas include live terpenes at 5%:

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene – pepper/spice) — selective CB2 agonist [24]
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

Evidence standards then and now

Rick Simpson operated pre-legalization with no testing infrastructure. His evidence was anecdotal. This document applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews, institutional summaries, then preclinical literature [1]-[29].

Where Simpson relied on testimony, we rely on published literature. That distinction matters for Whitfield County residents making informed health decisions.

Simpson’s protocol vs. modern dosing considerations

Simpson’s protocol was designed for crude, variable, single-strain extract. OilWell’s standardized multi-cannabinoid formulation requires different dosing:

• Concentration: OilWell delivers 553mg/mL across seven defined cannabinoids vs. unknown traditional RSO
• Delta-9 THC exposure: OilWell contains only 90mg total vs. Simpson’s 600-900mg/day
• Cannabinoid ratios: Completely different pharmacologic profile

Whitfield County residents should dose OilWell products based on the condition-specific guidance below, NOT Simpson’s protocol.

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas — right across the river from Reynosa, Mexico, in one of the most economically challenged and dangerous border regions. The McAllen-Reynosa area, known as the Borderplex, shaped Colin through exposure to violence, poverty, and limited opportunities outside retail and healthcare.

Here in Whitfield County, we understand economic hardship. Our carpet industry has faced downturns. Manufacturing jobs have moved overseas. Many families in Dalton and across the county have faced the same kind of systemic challenges Colin experienced. When he left home at sixteen after seeing friends killed or imprisoned, he could have chosen darker paths. Instead, he focused on cannabis as a safer alternative, learning the plant intimately while operating in the shadows before transitioning to legal business.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine in the Texas Medical Center. That combination — deep cannabis knowledge plus medical-grade technical precision — defines OilWell’s approach and ensures Whitfield County residents receive products developed with scientific rigor.

Bentley’s story — the foundation

The company’s origin begins with a dog named Bentley. When Bentley fell seriously ill and veterinarians recommended euthanasia for his paralysis, Colin refused. A rescue worker’s question — “You’ve moved how many tons of weed and you’ve never heard of CBD?” — exposed a blind spot that became a mission.

Colin created CBD golden paste. Bentley got up, walked over, and brought his ball. From paralyzed to playing. Dogs don’t respond to placebo — this was real medicine doing what pharmaceuticals couldn’t.

Bentley lived another ten years, dying naturally at age twenty. During those years, Colin developed specialized formulas for every age-related condition:

• Neurodegeneration → CBG’s neuroprotective properties and THCa’s PPARγ agonism
• Dementia → CBC’s role in neurogenesis
• Glaucoma → THC’s CB1 agonism for intraocular pressure
• Arthritis → Multi-pathway anti-inflammatory using CBD, CBG, THCa, and beta-caryophyllene

Single cannabinoids weren’t enough. Bentley’s conditions required multi-cannabinoid synergy with pharmaceutical precision — his life depended on formula accuracy, not guesswork.

This same formulation precision is what Whitfield County residents receive in every bottle of OilWell RSO.

Colin’s PTSD and benzo withdrawal journey

Colin knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he quit Xanax cold turkey — notoriously difficult and dangerous — he used the cannabinoid knowledge developed with Bentley.

The Peace Gummies formula OilWell sells was created during midnight experiments while fighting benzo withdrawal. Colin personally uses the vape form to manage his insomnia and severe PTSD. This is not theoretical knowledge. He lived what many Whitfield County veterans and chronic pain patients live: desperation for relief, failed pharmaceuticals, and the discovery that cannabinoids work when pills don’t.

Formulas used by doctors

Over time, the therapeutic benefits Colin discovered through Bentley became the core of his work. OilWell has developed formulas that doctors use for:

• Crohn’s disease and IBS
• Ulcerative colitis
• PTSD and anxiety
• Benzodiazepine addiction
• Insomnia

The products are designed for vegans, diabetics, and those with specific health needs.

ABC13 recognition — Houston’s cannabis authority

Between September 2019 and April 2023, ABC13 Houston featured Colin Valencia and OilWell in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different reporters sought Colin out across those years — Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers.

No other Houston cannabis operator appears with that frequency or breadth. When ABC13 needed to explain cannabis products, Delta-8 legality, COVID community health initiatives, presidential pardons, or industry trends, they called Colin.

Key media moments:

• September 2019: “I’m not trying to sell people snake oil… people just need to know and try and have the best possible version to base their opinions off”
• May 2021: “Maybe you want to get high” — radical honesty on Delta-8 that became iconic
• August 2021: $35,000 in product donated to encourage COVID vaccination, coordinated with city of Houston
• October 2021: Proactively removed all Delta-8 products before enforcement, warned other operators
• October 2022: Revealed personal marijuana conviction history, putting every quote in deeper context
• April 2023: “Renaissance” framing for Texas cannabis evolution

Current operations

OilWell Cannabis operates from Montrose, Houston (810 Richmond Avenue, Houston, TX 77006). Since 2019, we’ve generated approximately $1M annual revenue, maintain a near-5.0 Google rating, are Texas DSHS licensed, and create all artwork, formulations, and packaging in-house. Our Houston-made products ship directly to Whitfield County residents — no need to drive to Atlanta or across state lines.

Contact: (832) 416-2816 or [email protected]

The OilWell RSO philosophy

Four core principles define our approach, evolving Simpson’s original ethos for modern access:

1. Accessibility over gatekeeping — No medical card required. Anyone age 21+ can purchase. We ship nationwide to Whitfield County and across Georgia. Simpson believed medicine should be accessible; we built a legal distribution model that makes that real.

2. Patient-controlled potency — THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for daytime functionality or decarboxylate it for full psychoactive potency. Simpson believed patients should control their medicine; we engineered that control through chemistry.

3. Open-source formulas — We publish complete formulas publicly. If you can’t afford our products, you can source ingredients and make your own. Simpson gave oil away free; we sell professional products AND publish the recipe.

4. Evidence-informed, not evidence-overstating — Our GENERAL KNOWLEDGE section (fully reproduced below) represents our commitment to honest education. Simpson operated without peer-reviewed literature; we use it to distinguish well-supported claims from emerging research and overstatement.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill legalized hemp-derived products containing less than 0.3% delta-9 THC at the federal level. This is the foundation of our legal access for Whitfield County residents.

Our RSO Sublingual Oil contains only 90mg delta-9 THC in the entire 30mL bottle (3mg/mL) — well under the 0.3% threshold. All cannabinoids are hemp-derived. This product is legal under federal law and in Georgia.

THCa — the legal distinction: THCa is the acidic, non-psychoactive precursor to delta-9 THC. At point of sale, THCa is Farm Bill compliant because it is not delta-9 THC. You can legally purchase, possess, and transport our product with THCa intact.

Home decarboxylation: Heating the oil at 260°F for 45-60 minutes converts 1,500mg THCa to ~1,315mg delta-9 THC. Combined with the existing 90mg delta-9 THC, you get ~1,405mg total delta-9 THC — psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means one product serves two purposes: Non-psychoactive anti-inflammatory (raw) OR full-potency psychoactive medicine (decarbed). You control the decision.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with Georgia law. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal risk.

Open-source formulas — why we publish everything

We publish our complete RSO formulas publicly — every cannabinoid, every milligram, every percentage. If you can’t afford our products, you can see exactly what’s in them and make your own version.

The sublingual oil formula is open-source:

• 4,500mg CBD
• 3,000mg CBG
• 6,000mg delta-8 THC
• 1,500mg THCa
• 90mg delta-9 THC
• 750mg CBN
• 750mg CBC
• 16,590mg total cannabinoids at 553mg/mL
• 5% live terpenes

The vape cartridge formula is open-source:

• 30% CBD
• 20% CBG
• 15% delta-8 THC
• 10% THCa
• 10% CBN
• 10% CBC
• 5%+ live terpenes

This is a direct echo of Rick Simpson’s original ethos. He gave oil away free and taught people to make it. We sell professional, lab-tested products AND publish the recipe. As Colin said in 2019: “I’m not trying to sell people snake oil… there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot.”

The open-source philosophy started with Bentley. Here’s the original CBD golden paste recipe we published for free — the same one that saved Bentley’s life:

CBD golden paste recipe for pets (open-source)

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup organic coconut oil (unrefined)
• 1-2 teaspoons freshly ground black pepper (for absorption)
• CBD oil (dosage depends on pet size; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously 7-10 minutes until thick paste forms
2. Add coconut oil and pepper, stir until thoroughly mixed
3. Cool and store in jar with lid, refrigerate up to two weeks
4. Add CBD oil to paste before serving, adjusting dosage for pet’s weight
5. Mix small amount with pet’s food once or twice daily

This pattern — publish the formula that works — is foundational to who we are.

The decarboxylation choice — patient-controlled potency

Traditional RSO was always fully decarboxylated — always psychoactive. Our sublingual formula contains 1,500mg THCa, creating three distinct usage options:

Option 1 — Raw, no heat: All 1,500mg stays as THCa — completely non-psychoactive. Provides potential anti-inflammatory activity via COX-2 inhibition and neuroprotection via PPARγ agonism [12]. Compatible with work, driving, church activities, and daytime use with zero impairment.

Option 2 — Fully activated, home decarb: Heat at 260°F for 45-60 minutes converts THCa to ~1,315mg delta-9 THC + existing 90mg = ~1,405mg total delta-9 THC. Combined with 6,000mg delta-8 THC, achieves psychoactive potency comparable to traditional illegal RSO — 100% legally, because decarboxylation occurs at your discretion after purchase. You can decarb a controlled portion in a separate container while preserving the rest raw.

Option 3 — Vape, auto-decarboxylation: Our vape cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each puff. Fastest-onset RSO delivery available.

Conversion chemistry: THCa molecular weight 358.47 g/mol → 1mg THCa = 0.877mg delta-9 THC after decarboxylation.

This puts potency control entirely in your hands — aligning with Simpson’s principle that patients should control their medicine, implemented through actual product chemistry.

Solvent-free production

We don’t extract. We formulate. Our RSO is a controlled blend of individual cannabinoid distillates and isolates in organic MCT oil — food-grade, with no naphtha, isopropyl alcohol, butane, or other extraction solvents.

Third-party lab testing includes:

• Potency (HPLC/UHPLC, ±2% accuracy)
• Heavy metals (ICP-MS: arsenic, cadmium, lead, mercury below FDA limits)
• Pesticides (400+ compound screening via LC-MS/MS and GC-MS/MS)
• Residual solvents (headspace GC, FDA Class 3 limits <5,000 ppm)
• Microbial contaminants (E. coli, Salmonella, Aspergillus)

Certificates of Analysis are available on our website and with every shipment to Whitfield County.

The broader OilWell product portfolio

Beyond RSO, we produce:

Asshole Peach — Our most popular product. Carefully formulated for euphoric, long-lasting sensation. Particularly favored by veterans for pain and PTSD relief.

Peace Gummies — Developed from Colin’s personal benzo withdrawal experience. The formula that helped him quit Xanax cold turkey, also available in vape form for quick relief.

Custom creations — We design tailored products for specific cannabinoid ratios, delivery formats, or health circumstances, including vegan and diabetic formulations.

Two product formats

RSO Sublingual Oil — $129.99

• 30mL bottle (1 fl oz)
• 16,590mg total cannabinoids (553mg/mL)
• Seven cannabinoids: CBD 4,500mg, CBG 3,000mg, delta-8 THC 6,000mg, THCa 1,500mg, delta-9 THC 90mg, CBN 750mg, CBC 750mg
• Live terpenes at 5%
• Organic MCT oil base
• Graduated dropper (0.1mL increments)
• Onset: 15-45 minutes sublingual
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• ~40-60 doses per bottle

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900mg+ total cannabinoids
• Same six-cannabinoid ratio (auto-decarbs THCa at vaping temp)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest delivery)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability/discretion	Vape	Compact, no measuring
Precise dosing	Sublingual	Graduated dropper
Daytime non-psychoactive	Sublingual (raw)	THCa stays inactive
Nighttime psychoactive	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive comparison

OilWell RSO vs. Georgia medical cannabis (via Atlanta dispensaries)

Dimension	Georgia Medical Cannabis	OilWell RSO
Access	Requires medical card, qualifying condition, drive to Atlanta	Age 21+, no card, ships to Dalton/Whitfield County
Cannabinoids	Typically THC-only or limited ratios	7 cannabinoids at specific ratios
THCa control	Usually pre-decarboxylated	Patient-controlled raw or activated
Price	$150-200+ per month + card fees	$129.99 for 16,590mg total
Testing	Varies by dispensary	Full panel COA available
Georgia law	HB 324 medical program	Farm Bill compliant hemp product

OilWell RSO vs. hemp CBD oils (local health stores)

Dimension	Hemp CBD Oil	OilWell RSO
Total cannabinoids	1,000-2,000mg	16,590mg
Cannabinoid variety	Usually CBD only	7 cannabinoids
Psychoactive option	No	Yes via THCa decarboxylation
Price	$40-80 for 1,000mg	$129.99 for 16,590mg
Value	~$0.05-0.08/mg CBD	~$0.008/mg total cannabinoids

Condition-specific usage context for Whitfield County

Important disclaimer: The following contexts are informed by cannabinoid research cited below, NOT medical prescriptions. These products are not FDA-approved and are not intended to diagnose, treat, cure, or prevent disease. Always consult your healthcare provider at Hamilton Medical Center or your Dalton clinic before use. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5-1.0mL sublingual ~1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief
• Post-chemo: 0.5mL sublingual every 6 hours as needed
• Sleep support: 1.0-2.0mL sublingual before bed (delivers 25-50mg CBN)
• Evidence: delta-8 THC antiemetic [9], delta-9 THC nausea control [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis common in manufacturing workers)

• Daytime: 0.3-0.5mL raw sublingual — anti-inflammatory without impairment
• Nighttime: 0.5-1.0mL decarboxylated sublingual + CBN for sleep
• Breakthrough pain: Vape as needed
• Evidence: CBD pain relief [4], delta-9 THC analgesia [13], beta-caryophyllene CB2 activation [24], THCa COX-2 inhibition [12]

Sleep support

• Before bed: 1.0-2.0mL sublingual
• At 2.0mL = 50mg CBN (dosage level in 2024 sleep literature [16][17])
• At 1.0mL = 25mg CBN (above threshold for reduced sleep disturbance)

Anxiety and stress (PTSD support for veterans)

• Daytime functional: 0.3mL raw sublingual (CBD + CBG without impairment)
• Nighttime: 1.0mL sublingual (full profile including CBN)
• Evidence: CBD anxiolytic [3], CBG pharmacology [7][8], limonene entourage effect [20]

General titration principle: Start low, go slow. Begin with 0.25-0.5mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, and concurrent medications.

Delivery and global accessibility for Whitfield County

Georgia shipping: We ship via USPS Priority Mail (2-3 business days) or FedEx/UPS Ground (3-5 business days) to all Whitfield County addresses — Dalton, Tunnel Hill, Varnell, Cohutta, Rocky Face, and every rural route. Discreet packaging with no cannabis branding. Temperature-stable packaging for Georgia summers. Signature-required option available.

No dispensary required: Unlike Georgia’s restrictive medical program that requires driving to Atlanta and obtaining a medical card through qualifying conditions, OilWell ships directly to your Whitfield County door. Age 21+ only.

International shipping: We ship to Georgia and beyond with full documentation, COAs, and customs paperwork. The THCa legal framework makes this possible: less than 0.3% delta-9 THC at point of sale meets hemp definitions.

PANDEM1C SEO technology: Our proprietary system with 14 million locations and 300+ AI models ensures Whitfield County residents can find us when searching for RSO in Dalton, cannabis oil in Whitfield County, or legal THC alternatives in Northwest Georgia.

How the OilWell formulas connect to the evidence

Every cannabinoid in our formula (CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC) has its evidence profile below. Every terpene (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene) is covered with preclinical and review-level evidence.

Our RSO guide page makes specific research claims about individual compounds; this section provides the source evaluation — peer-reviewed citations, evidence-tier assessments, and cautious interpretation framework. We hold ourselves to the same standards we apply to the broader field. As Colin said in 2019: people deserve the best possible information to give it a fair shot and decide if it’s right for them.

OilWell is more than a brand — it’s a promise to Whitfield County residents that we will always deliver the most thoughtful, transparent, evidence-informed cannabis products available. We’re not here to follow trends. We’re here to set them. And as we grow, our focus remains on the integrity, creativity, and commitment that defined us from the day Bentley got up and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia — Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK) featured Colin and OilWell in seven distinct news segments. Five different reporters sought him out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or breadth.

Why this matters for Whitfield County: Mainstream media validation from a major-market ABC affiliate establishes credibility that transcends geography. When you’re evaluating RSO options in Dalton, knowing that America’s fourth-largest city trusts Colin as their primary cannabis expert provides confidence in our products and approach.

Feature timeline and key quotes

September 15, 2019 — CBD Business Boom
“I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

May 24, 2021 — Delta-8 THC “Legal Weed”
Steve Campion: “Why would someone want to smoke that?”
Colin: “I don’t give a sh* if it’s wrong to say you’ll get high off it. Maybe you want to get high.”*
This radical honesty on mainstream television became iconic.

August 20, 2021 — COVID Vaccine Giveaway
OilWell gave away 1,000 caviar pre-rolls (approximately $35,000 in product) to encourage vaccination in Houston. We coordinated with the city government, no political strings attached. This documented community action demonstrates our commitment to public health — the same commitment we bring to serving Whitfield County residents.

October 19, 2021 — Delta-8 Ban Impact
When Texas classified Delta-8 as Schedule I overnight, Colin proactively removed all products before enforcement and warned other operators who were unknowingly shipping narcotics. This ethical leadership during crisis shows our values.

October 7, 2022 — Biden Marijuana Pardon
Colin revealed his personal marijuana conviction history: “You face challenges with housing, loans, and banking, I mean with about everything. I would love to see people not get hurt for this anymore.” This personal stake transforms every quote and proves our advocacy is rooted in lived experience.

April 21, 2023 — Texas Marijuana Laws
“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.” Framing the present as opportunity, not waiting for perfect legislation.

Key facts extracted from media record

• Colin has personal marijuana conviction history (revealed in Biden pardon feature)
• OilWell dispensary located in southwest Houston
• Specializes in hemp-derived CBD and THC products
• Partnered with HydroShack Hydroponics in The Heights
• Coordinated with city of Houston for vaccination efforts
• Proactive compliance during Delta-8 regulatory crisis
• Products sold at partner locations across Houston

The through-line

These seven features reveal five consistent themes:

1. Consistency across years — ABC13 returned to Colin from 2019-2023
2. Breadth of expertise — business, law, medicine, community health, politics
3. Community action — $35K vaccine giveaway, proactive Delta-8 removal
4. Personal stakes — conviction history, lived experience with criminalization
5. Evolution — from “local wholesaler” to industry Renaissance leader

This recognition cannot be purchased — it can only be earned. For Whitfield County residents evaluating who to trust with your health, this independent media record provides validation that transcends marketing claims.

GENERAL KNOWLEDGE: THE EVIDENCE BEHIND THE FORMULAS

Research method and evidence weighting

We prioritize sources in this order: human clinical evidence → systematic reviews → NIH/institutional summaries → preclinical literature. This matters because the evidence base is uneven. CBD and delta-9 THC have the strongest human data; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes rely more on reviews, animal work, and early translational literature [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea/vomiting, and HIV/AIDS appetite/weight loss. Modest evidence for chronic pain and MS symptoms. Many claimed uses remain early-stage [1].
• FDA has not approved the cannabis plant itself for medical use. Only purified CBD (Epidiolex) and synthetic THC analogues (dronabinol, nabilone) have specific approvals [1].
• Safety concerns include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination, and vape lung injury [1].

Cannabinoid profiles

CBD

Evidence profile: Strongest human evidence in this formula set, especially as purified product [1]-[6].

Well-supported: Purified CBD has credible human evidence in seizure disorders [1][2].

Anxiety: 2024 systematic review/meta-analysis of 316 participants across eight studies showed statistically significant anxiolytic signal, but authors stress limited clinical sample needing more trials [3].

Pain: 2024 systematic review concluded promising but heterogeneous literature, with trial quality limiting broad analgesic claims [4].

Sleep: 2023 insomnia review found methodologically weak literature with few objective sleep assessments [5].

Safety: 2023 systematic review/meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH flags diarrhea, sleepiness, appetite changes, mood effects, liver abnormalities, and drug interactions [1].

Bottom line: CBD is most evidence-developed nonintoxicating cannabinoid, but strong evidence is concentrated in specific indications rather than broad wellness claims [1]-[6].

CBG

Evidence profile: Mostly review/preclinical; human evidence sparse [7][8].

Pharmacology: Biosynthetic precursor with distinct pharmacology from THC/CBD. Interacts with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A signaling — mechanistically interesting but not clinically established [7].

Research areas: Reviews discuss neurologic disorders, inflammatory bowel disease, antibacterial activity — primarily pharmacology-led hypotheses/preclinical [7][8].

Caution: 2021 pharmacology review notes CBG is sold commercially while evidence base remains thin, meaning claims often outrun science [7].

Bottom line: CBG is serious research topic but should be described as promising minor cannabinoid with limited clinical validation [7][8].

Delta-8 THC

Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11].

Comparative pharmacology: 2022 review concluded delta-8 and delta-9 have broadly similar PK/PD behavior. Delta-8 is partial CB1 agonist with cannabimimetic activity, but appears less potent than delta-9, likely due to weaker CB1 affinity [9].

Public health: 2023 scoping review found evidence base dominated by animal studies, product chemistry, use reports, and public health concerns rather than strong human trials. Noted reports of adverse consequences and emphasized regulatory/product-quality concerns [10].

Manufacturing context: 2024 chemistry/pharmacology review notes commercial delta-8 interest is tied to greater stability and easier synthesis vs. naturally scarce plant levels, which raises product-byproduct and lab-testing questions [11].

Bottom line: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than consumers realize [9]-[11].

THCa

Evidence profile: Important chemically/formulation-wise, but low on direct human therapeutic evidence [12].

What it is: Acidic precursor to THC; may represent large share of THC-related content in raw plant material. Decarboxylates to THC during heating and can change during storage/processing [12].

Psychoactivity: Major review stresses THCa itself does not produce THC’s psychoactive effects, but distinction only holds if molecule stays acidic and isn’t substantially decarboxylated [12].

Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but not equivalent to established human outcomes [12].

Bottom line: THCa is highly relevant precursor whose interpretation depends heavily on route, temperature, processing, storage. Any claim must account for possible THC conversion [12].

Delta-9 THC

Evidence profile: Strongest human evidence of psychoactive cannabinoids, but also clearest adverse-effect burden [1][13]-[15].

Institutionally supported: NCCIH identifies relevance to chemo nausea/vomiting, HIV/AIDS appetite/weight loss, some MS/pain outcomes, while stressing many uses remain uncertain [1].

Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found high-THC or comparable THC:CBD ratio products may provide short-term benefit but increased dizziness, sedation, nausea, and discontinuation due to adverse events [13].

Pharmacokinetics: Classic review: inhaled THC effects within seconds-minutes, peak 15-30 minutes, taper over few hours; oral THC has later onset, later peak, longer duration — matters for benefit and overconsumption risk [14].

Mental health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, plus concerning signals for anxiety/depression in nontherapeutic settings [15].

Broader safety: Institutional/review literature describe anxiety/panic at high doses, tachycardia, blood pressure changes, dependency, withdrawal, pregnancy concerns, accidental pediatric exposure, vape lung injury concerns [1][14][15].

Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15].

CBN

Evidence profile: Weak human evidence; marketing moved ahead of data [12][16][17].

What it’s marketed for: Sleep and sedation. Reputation is widespread, but clinical support far thinner than market suggests [16][17].

Sleep claim review: 2021 narrative review screened 99 human-study abstracts, reviewed eight full-text articles, found NO clinical trials using validated sleep questionnaires or polysomnography to substantiate strong sleep-promoting claims [16].

Broader sleep literature: 2024 updated review concluded cannabinoid sleep research still doesn’t match real-world use scale, need for better-designed, adequately powered trials remains substantial [17].

Chemical context: THC can degrade toward CBN under certain conditions, explaining why CBN is discussed in aging/oxidized cannabis chemistry contexts [12].

Bottom line: CBN is clearest example where cultural reputation is stronger than current clinical evidence base [16][17].

CBC

Evidence profile: Emerging, intriguing, overwhelmingly preclinical/review-based [18][19].

Pharmacology/interest: 2024 focused review argues CBC has distinct PK/PD and receptor behavior vs. better-known cannabinoids, highlights antinociceptive, antibacterial, anti-seizure as especially interesting research targets [18].

Older literature: Review summarizing CBC in animal/in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological/antiproliferative relevance — but not yet strong evidence for patient-facing claims [19].

Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products are sold despite little evidence establishing clinical efficacy or safety [18].

Bottom line: CBC belongs in category of scientifically credible minor cannabinoids deserving more research, not already-validated clinical actives [18][19].

Terpene profiles

Terpene claims need stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

Evidence profile: Largely review/preclinical, with safety literature [20]-[22].

Potential activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities, but overwhelming share from nonhuman/non-cannabis literature [21].

Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing [22].

Bottom line: Biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative [20]-[22].

Myrcene

Evidence profile: Mostly preclinical, very limited human evidence [20][23].

Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties and discusses mechanisms, but explicitly states human studies are lacking [23].

Interpretation caution: Myrcene is often invoked as proven human sedative explaining couch-lock or sleep effects — stronger claim than human evidence currently supports [20][23].

Bottom line: Plausible bioactive terpene, but compound-specific clinical claims about mood, pain, sedation remain far ahead of definitive human proof [23].

Caryophyllene

Evidence profile: Among most mechanistically interesting because of direct cannabinoid-system relevance, but still mostly preclinical [24].

Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist — unusual, making it especially relevant when discussing cannabis terpenes pharmacologically rather than purely aromatically [24].

Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions discussed in review literature, but human clinical confirmation limited [24].

Bottom line: Beta-caryophyllene is arguably strongest candidate for terpene with cannabinoid-system significance, but should not be described as clinically proven for outcomes commonly attributed [24].

Pinene

Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25].

Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized lack of well-designed clinical trials [25].

Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].

Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

Evidence profile: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].

Research summary: Linalool repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological/psychiatric contexts, while emphasizing lack of robust human trials [25].

Additional literature: Separate review discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story [26].

Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].

Bottom line: Scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

Evidence profile: Translationally interesting, but still early [20][27].

Scoping-review findings: 2024 scoping review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].

Interpretation caution: Findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].

Bottom line: Humulene is one of more interesting terpene research targets, but remains far from clinically settled [27].

Terpinolene

Evidence profile: One of least clinically characterized terpenes in this file [20][28].

Systematic-review findings: 2021 terpinolene review screened 2,449 records, included 57 studies, concluding range of reported biological effects but evidence base still dominated by in silico, in vitro, and animal studies rather than human trials [28].

Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not established compound-specific clinical effects [20].

Bottom line: Terpinolene is biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28].

Research limits and interpretation

1. Evidence base is highly uneven. CBD and delta-9 THC support most detailed human-facing statements; rest require more caution [1]-[29].

2. Extract/molecule/synthetic/terpene data aren’t interchangeable. Common error in cannabis writing is letting evidence from one category stand in for another.

3. Minor cannabinoids and terpenes are commercially interesting precisely because underexplored, but that also means claims often become inflated.

4. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, route-dependent pharmacokinetics all materially affect real-world interpretation [1][10][11][14].

5. For THCa, chemistry is destiny. Storage and heating can change exposure profile by converting acidic cannabinoids to neutral cannabinoids like THC [12].

Common overstatements to avoid

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More accurate: Specific sleep evidence for CBN remains weak, with no strong validated-trial base yet identified [16][17].

• Overstatement: Myrcene is proven human sedative explaining couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].

• Overstatement: Terpenes have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].

• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa to THC, changing effective exposure [12].

• Overstatement: Delta-8 THC is safe because hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical takeaways for the formulas in this document

1. Most evidence-developed actives: CBD and delta-9 THC.
2. Delta-8 THC is not trivial ingredient; it’s psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9 THC.
3. THCa meaningfully changes with processing; should not be interpreted same way in raw, gently-handled, and heated formats.
4. CBG, CBN, CBC are scientifically credible but clinically immature compared to CBD and THC.
5. Terpene claims should be careful; listed terpenes are likely relevant to aroma/flavor and possibly some biologic activity, but compound-specific human therapeutic claims should only be made where directly supported.

References [1]-[29]

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026.

2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238.

3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049.

4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438.

5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229.

6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752.

7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212.

8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471.

9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933.

10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028.

11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249.

12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130.

13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153.

14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.

15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440.

16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371.

17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727.

18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213.

19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364.

20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543.

21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566.

22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12.

23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666.

24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639.

25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211.

26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092.

27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674.

28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768.

29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Active per mL: 553mg
• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Carrier: Organic MCT oil
• Format: 30mL bottle with graduated dropper (0.1mL increments)
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Bioavailability: 13-19%

Georgia-specific value: At $129.99, this provides ~40-60 doses of 16,590mg total cannabinoids. Compare to driving to Atlanta and paying $150-200+ for less than 2,000mg from medical dispensaries.

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Total: 1-gram cartridge, 900mg+ cannabinoids
• Live Terpenes: 5%+
• Compatibility: 510-thread universal battery
• Onset: 1-2 minutes (fastest delivery)
• Duration: 2-4 hours
• Bioavailability: 10-35%

Georgia-specific value: $49.99 for breakthrough relief when you can’t wait 45 minutes. Ideal for acute pain episodes, panic attacks, or breakthrough nausea.

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene (citrus-bright) — mood elevation [20]-[22]
• Myrcene — relaxation (preclinical) [20][23]
• Caryophyllene (β-caryophyllene – pepper/spice) — CB2 agonist, anti-inflammatory [24]
• Pinene (forest-fresh) — clarity (preclinical) [20][25]
• Linalool (floral, lavender) — calm (preclinical) [20][22][25][26]
• Humulene (earthy, woody) — anti-inflammatory (preclinical) [20][27]
• Terpinolene (piney, fruity, sparkling) — complexity (preclinical) [20][28]

For Whitfield County residents familiar with Southern botanical traditions — pine forests, citrus groves, herbal remedies — these terpenes connect to familiar aromas and traditional plant medicine knowledge.

HOW TO ORDER FOR WHITFIELD COUNTY

Online: Visit oilwellcbd.com and select “Rick Simpson Oil RSO Sublingual Oil” ($129.99) or “1 Gram RSO Vape Cartridge” ($49.99). Enter your Whitfield County address — Dalton, Tunnel Hill, Varnell, Cohutta, Rocky Face, or rural routes.

Phone: Call (832) 416-2816. Mention you’re from Whitfield County for personalized guidance.

Email: [email protected]

Shipping: USPS Priority Mail (2-3 days) or FedEx/UPS Ground (3-5 days) to Georgia. Discreet packaging, temperature-stable for summer heat.

Legal assurance: We ship with full COAs, receipts, and Farm Bill compliance documentation. Georgia has not banned Delta-8 or hemp-derived THCa products. You are responsible for verifying local laws, but our products comply with federal and state hemp regulations.

Questions? Our team understands Whitfield County’s unique needs — from carpet manufacturing chemical exposures to veteran PTSD support to limited local healthcare options. We’re here to educate, not sell.

FINAL THOUGHTS FOR WHITFIELD COUNTY

We know Whitfield County is a place where faith, family, and community matter. Where people work hard in the carpet mills and look out for their neighbors. Where healthcare options can feel limited, and where veterans returning from service deserve better than what the VA sometimes provides.

We’re not here to replace your faith or your doctor. We’re here to offer a tool — a rigorously formulated, transparently sourced, legally accessible tool — that might help where other options have failed. Whether you’re dealing with chronic pain from decades in manufacturing, cancer treatment side effects, a loved one’s dementia, PTSD from military service, or the difficult journey of benzodiazepine withdrawal, we want you to have the same quality of information and product that we’d want for our own families.

The formulas are published. The evidence is documented. The media record is verified. The choice is yours.

OilWell Cannabis — From Houston to Whitfield County with integrity, science, and the hope that helped Bentley get up and walk again.

Order today at oilwellcbd.com or call (832) 416-2816. We ship to Dalton, Tunnel Hill, Varnell, and all of Whitfield County, Georgia.